Skip to main content
. 2023 Feb 22;30(1):2180113. doi: 10.1080/10717544.2023.2180113

Table 3.

Treatment-emergent adverse events reported during the study.

  Oxybutynin 100 mg (n = 8)
Event n Subject n (%)
All events 11 5 (62.5)
Eye disorders    
 Blurry vision 1 1 (12.5)
Gastrointestinal disorders    
 Dry mouth 1 1 (12.5)
 Lip dry 1 1 (12.5)
 Nausea 1 1 (12.5)
General and administration conditions    
 Fatigue 2 2 (25.0)
 Feeling hot 1 1 (12.5)
Nervous system disorders (headache) 4 3 (37.5)